Modafinil for the Pharmacological Stimulation of Wakefulness in Critically Ill Patients
Abstract
Objective: : Because of a number of factors critically ill patients are prone to develop cognitive problems, excessive daytime sleepiness (EDS) and fatigue during their intensive care unit (ICU) stay. Modafinil has potential advantages when used in patients to improve wakefulness, cognitive function and activity. The present article reviewed literature to describe modafinil use for the treatment of EDS and fatigue in ICU.
Methods:: For the present narrative review, an online search was conducted for studies referring to modafinil administration to improve wakefulness in the ICU. The search was performed on Embase, MEDLINE, Web of Science, and Google Scholar until May 20, 2025.
Results:: Nine relevant studies were identified. These included 2 RCTs, 2 case series and 5 retrospective studies. Four of these studies included TBI or post-stroke patients, while the rest comprised mixed ICU populations.
Conclusion:: Some data showing that modafinil may improve the wakefulness of selected critically ill patients and encourage their participation in physical therapy. Larger RCTs are essential to determine the role modafinil in the treatment of EDS and hypoactiveness in the ICU.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.